NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Tilray Brands, Inc. (TLRY) Stock Analysis

Tilray Brands, Inc. (TLRY) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

TLRY

$4.50

−$0.03 (−0.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TLRY with… →

TLRY Key Statistics

As of Sep 4, 2026
Trading
Open
$4.51
Previous Close
$4.53
Day's Range
4.45–4.54
52-Week Range
3.67–23.20
Volume
2.75M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.92
Valuation
Market Cap
$619.11M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.68
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.08
Financials (FY)
Revenue (FY)
$915.45M+11.46%
Net Income (FY)
−$121.40M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.26%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
137.58M
1-Year Return
−60.87%
Dividend and dates
Earnings Date
October 8, 2026
Avg Volume
4.00M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TLRY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−50.17%
2025−32.11%
2024−42.17%
2023−14.50%
2022−61.74%
2021−14.89%
2020−51.78%
2019−75.72%
2018 (partial year)+215.05%

As of September 4, 2026.

TLRY Revenue and Earnings by Fiscal Year

FY ends May
Fiscal yearRevenueNet incomeNet margin
2025$915.45M−$121.40M−13.3%
2024$821.31M−$2.19B−266.3%
2023$788.94M−$244.98M−31.1%
2022$627.12M−$1.45B−231.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$915.45M$260.44M−$55.26M−$121.40M−13.3%
2024$821.31M$240.57M−$107.81M−$2.19B−266.3%
2023$788.94M$223.35M−$112.76M−$244.98M−31.1%
2022$627.12M$146.96M−$178.20M−$1.45B−231.6%

Annual figures as reported, in the company's reporting currency. As of May 31, 2026.

TLRY Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricTLRYDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.682.300.3x the median
Profit margin−13.26%−3.14%10.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tilray Brands, Inc. (TLRY) at $619.11M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 3,595.

TLRY last closed at $4.50 on September 4, 2026. That is −$0.03 (−0.66%) against the previous close. The 52-week range on file runs from $3.67 to $23.20. The latest close sits 22.62% above that 52-week low.

Financial Health

In fiscal 2025, Tilray Brands, Inc. reported revenue of $915.45M. That is +11.46% against the prior fiscal year, when revenue was $821.31M. The same year closed with a net loss of $121.40M. The reported profit margin is −13.26%. That is 10.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −1.08.

Across the 4 fiscal years on file, revenue moves from $627.12M in 2022 to $915.45M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 10. Measured against sales, the shares trade at 0.68 times revenue. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −60.87%. Measured over 5 years, that is −49.42% a year compounded. Beta against the wider market is reported at 1.92. Annualized volatility over the trailing 8 years is 109.25%.

Growth & Income

No dividend is on file for TLRY.

2026 is still running; the price is −50.17% year to date. The strongest complete calendar year on file is 2023 at −14.50%; the weakest is 2019 at −75.72%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Tilray Brands, Inc. (TLRY) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tilray Brands, Inc. TLRY $619.11M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Tilray Brands, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tilray Brands, Inc.

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Shock Top, Montauk Brewing, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point, Alpine, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Cruisies, Atwater Brewery, Hi-ball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Visit website →